Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Orca-T Approved to Prevent GVHD After Stem Cell Transplant for Blood Cancers

2.

In leukemia, allogeneic HCT is beneficial following primary induction failure.

3.

Geriatric Assessment, QoL Correlate With OS in Older Patients with Pancreatic Cancer

4.

Guideline on management of early-stage non-small cell lung cancer released

5.

New Standard for Newly Diagnosed Pediatric B-Cell Acute Lymphoblastic Leukemia


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot